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The classical complement pathway is initiated by the large (~800 kDa) and flexible mul-
timeric C1 complex. Its catalytic function is triggered by the proteases hetero-tetramer
C1r2s2, which is associated to the C1q sensing unit, a complex assembly of 18 chains
built as a hexamer of heterotrimers. Initial pioneering studies gained insights into the main
architectural principles of the C1 complex. A dissection strategy then provided the high-
resolution structures of its main functional and/or structural building blocks, as well as
structural details on some key protein–protein interactions.These past and current discov-
eries will be briefly summed up in order to address the question of what is still ill-defined.
On a functional point of view, the main molecular determinants of C1 activation and its
tight control will be delineated.The current perspective remains to decipher how C1 really
works and is controlled in vivo, both in normal and pathological settings.
Keywords: classical complement pathway, C1 complex, C1r, C1s, C1q, serine protease activation, complement-
dependent cytotoxicity, X-ray structures
INTRODUCTION
In 1897, at the very early period of nascent immunology, the Nobel
price winner Jules Bordet discovered a heat-sensitive serum effec-
tor triggered by immune complexes and absolutely required for
the lysis of Ab-coated erythrocytes or bacteria. At that time, it was
named “alexine.” As discovered later on, this effector mechanism
is very complex, involving many proteins, namely the comple-
ment system (C) triggered via the classical pathway (CP) (1, 2)
(see Figures 1A,B). Deciphering the fine structural mechanisms
governing this CP-activating function of the first C component
C1 remains experimentally difficult and has progressed through
iterative steps, which will be briefly summarized here.
Why is it important to decipher C1 structure and C activa-
tion mechanism? One obvious aim is to improve the C1-mediated
effector mechanism in antibody therapeutics (8). C1 plays indeed
a crucial role in the efficient elimination of Ab-coated targets, as
confirmed by the disease susceptibility of patients affected by the
deficiency in components C1q, C1r, C1s, and C4, all involved in
the CP activation (9). Another hallmark of these deficiencies is
the very large propensity to develop autoimmune diseases such as
lupus erythematosus, which underlines that other essential func-
tions are provided by the CP activation (9–13). On the other side,
non-physiological activation of the CP or interferences by foreign
substances such as carbon nanomaterial (14, 15) or a defective
control of CP activation can also be strongly detrimental. Such
undesirable activations can happen for example in cases of trans-
plantation, neurological disorders, and rheumatoid arthritis (16)
and thus new strategies to specifically inhibit the CP are awaited.
On a more general standpoint, the functional impact of the com-
plement system appears now far broader and more essential than
initially assumed (17, 18).
INITIAL STUDIES AND FIRST LOW RESOLUTION
FUNCTIONAL C1 MODELS
Very active pioneering investigations were performed during the
1963–1987 period (1–3, 19). The sequences of the C1q, C1r, and
C1s subcomponents, their fixed (C1q:C1r2s2) stoichiometry, as
well as the calcium-dependency of the interaction between C1r
and C1s have been deciphered. Biochemical experiments revealed
that C1r and C1s are sequentially activated (Figure 1A) and their
unique Arg-Ile activation cleavage site has been precisely iden-
tified (3). In both cases, a disulfide bridge maintains a covalent
link between the catalytic serine protease (SP) domain and the
preceding modules. Careful protein biochemical analyses detailed
the numerous C1q post-translational modifications such as pro-
line and lysine hydroxylations and hydroxylysine glycosylations,
which were mainly confirmed recently (20). The main functional
domains were isolated by limited proteolysis of the serum-derived
proteins and their shape studied by several biophysical meth-
ods such as small angle X-ray or neutron scattering and electron
microscopy (21–23) (see Figure 1C). C1q is a very flexible 450 kDa
molecule, partly stabilized by the associated protease tetramer
(24). Catalytic and interaction domains were identified for each
C1r and C1s protease (Figure 1C). In an apparent paradox, a very
elongated shape was observed by neutron scattering for the pro-
tease tetramer in solution (larger maximum radius of gyration Rg
of 17 nm) in contrast to the measures for C1q (Rg of 12.8 nm)
and for the C1 complex (Rg of 12.6 nm), which suggested a sub-
stantial conformational change of the tetramer and/or C1q upon
association (Figure 1C) (3, 25). The other intriguing feature was
about the symmetry level inside the complex since the C1q hexa-
mer associates with a proteases tetramer (19, 24). Several “low
resolution” models were proposed for C1 at that time, the main
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FIGURE 1 | Functional and structural elements of the CP activation.
(A)The main steps of the complement activation cascade through the CP.
The multimeric C1q molecule is associated to the C1s–C1r–C1r–C1s
tetramer. When C1q binds to an activating target surface, a
conformational change triggers the auto-activation of the associated C1r
protease (converting the pro-enzyme into an activated form, black circular
arrow), which then activates C1s (black arrow). C1s activates C4 and
C4b-bound C2 (red arrows), leading to the assembly of the classical C3
convertase C4b2a. Green arrows are used for the activation cleavage of
C2, C3, and C4, with the release of a small fragment. Details of the
consecutive AP amplification loop are not given for sake of clarity. It
involves C3–C9 components and mediates rapid opsonization, signaling
events, as well as eventually formation of the lytic pore. The initial steps
are numbered from 1 to 5. The first two steps occur inside C1 and depend
on C1q conformational change and the consequent C1r activation. Steps
3 and 4 depend on C1s proper positioning and catalytic activity.
(B) Current hypothetical schemes on similar interaction modes between
C1q and IgM or IgG hexamers, the best CP activators. The new scheme
proposed for IgG is in contrast with the traditional old scheme (right)
depicting one C1q molecule interacting with two distant IgG molecules,
each antigen-bound through its two Fab arms. (C)The “C1 paradox” and
initial low resolution C1 models. C1 is a 30 nm high multimer resulting
from the association of the flexible recognition protein C1q with the
flexible C1s–C1r–C1r–C1s tetramer, which appears more elongated (S
extended shape) in solution than in the complex (thus the initial
“paradox”). C1q (yellow) has a hexameric shape, built from 18 chains.
Interaction (I) and catalytic (C) domains of C1r and C1s are labeled and
colored on the right side. The asterisks show the position of flexible
hinges in C1q. The low resolution model on the left and the proposed
tetramer conformational equilibrium on the right are derived from (3).
(D) Modular structure of each C1q chain type. A, B and C chains associate
as a hexamer of ABC heterotrimers. Kink indicates the position of
disruptions in the triplets occurring only within collagen-like sequences of
the A and C chains and probably inducing flexible hinges. The disulfide
bridging between chains A and B is illustrated. The C chain has no
covalent link with A and B chains, but covalently associates pairs of ABC
trimers through a C–C disulfide bridge. The two lysines crucial for C1
assembly are shown in pink. (E) Modular structure and associated
functions of C1r and C1s. The catalytic domain includes the C-terminal
serine protease (SP) domain as well as the preceding Complement
Control Protein (CCP or sushi) modules. The interaction domains of C1s
and C1r involve their N-terminal CUB–EGF–CUB modules. The
corresponding functional implications are mentioned. The same color
coding is used in (F,G) and in the right panel of (C). “CUB” means initially
found in Complement C1r and C1s, Uegf and BMP-1. (F) C1 is a large
complex made of small building blocks of (mainly) known structures. The
displayed C1s is a composite structure obtained after superposing the
PDB structures 1ELV (4) and 4LMFA (5) onto 4LOT (5) (see details in Table
S1 in Supplementary Material). The color code used is the same as in
(C,E). The chains ABC from the C1q globular domain [2WNV (6)] are
shown on the same scale. (G) Example side view of a partial composite
C1 model, refined using the results of differential accessibility in C1q and
C1 using chemical lysine labeling followed by mass spectrometry (7). The
C1r and C1s proteases interact with C1q through their interaction
domains aligned on the same plane (which corresponds to the position of
LysB61 and LysC58 in C1q). This part of the model is mainly confirmed by
recent complementary experimental studies (8). The position of the
catalytic domain of C1s is more uncertain and probably variable.
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differences being the speculations about its activation mechanism
and on how the proteases are tightly packed inside C1, and whether
they are fully kept inside the C1q cone or not (3, 19, 24, 26).
THE MAIN MOLECULAR PLAYERS INVOLVED IN C1
ACTIVATION AND ITS TIGHT CONTROL
The C1r and C1s proteases are produced as inactive precursors
(called zymogens), and thus need to be activated “on the spot”
by a specific Arg-Ile proteolytic cleavage in response to a trig-
gering signal. This activating cleavage induces a conformational
rearrangement, as classically described for the proteases of the
trypsin-like family. C1-inhibitor, a protease inhibitor of the ser-
pin family, exerts the main physiological control on these C1r
and C1s proteases activity, by both inhibiting their activation
and dissociating them from activated C1. C1 auto-activation can
be observed in vitro in the absence of C1 inhibitor or through
heating, which induces large conformational changes and also
probably kills the C1-inhibitory effect (19). The adverse effects
related to uncontrolled C1 activation are thus mainly linked to
unbalanced C1-inhibitor control. C1-inhibitor is a multipotent
serpin, controlling also some proteases of the fibrinolytic system,
and contact/kinin system of coagulation in addition to the C1r,
C1s, and MASP complement proteases and thus its deficiency leads
to severe diseases such as hereditary angioedema (27).
IgM or IgG immune complexes are the best physiological C1
activators identified to date, especially in the presence of C1-
inhibitor. Although it has been known for long that C1q binds to
IgG Fc domain, and that activation requires multivalent binding,
the details of how this can happen had remained poorly under-
stood (8). IgG mutations are known to strongly influence C1q
binding and C activation (28–31). Of note, these mutation stud-
ies did not fully confirm the originally predicted E-x-K-x-K IgG
C1q-binding consensus motif (28), which remains, however, still
used by some teams as a C1q-binding predictive tool.
A recent study has shown how IgG surface clustering through
Fc-dependent hexamers could lead to very efficient C1 activation
(8) (Figure 1B). Interestingly, this mode of hexameric clustering
is far more similar to the pentameric/hexameric IgM assembly
than to what was traditionally proposed (Figure 1B). It has long
been described in text books that C1 activation involves bind-
ing to at least two IgG molecules, each one bound to the surface
through its two Fab segments (Figure 1B). In contrast, in the
recently proposed hexameric IgG assembly, each IgG seems to
have only one Fab arm on the target surface, the other Fab arm
lying on the same central plane as the clustered Fc platform (8).
This recent breakthrough brings new clues about how to enhance
the complement-dependent cytotoxicity of IgG, since the E345R
mutation was described as a general C1 activation enhancer for all
IgG isotype variants (8). The recent structure of the deglycosylated
IgG4 Fc further supports this hypothesis of a possible generic hexa-
meric Fc assembly, which is stabilized by this E345R mutation (32).
The IgG1 and IgG4 Fc form quite similar hexameric rings of 175 Å
diameter, which is of the same range of magnitude as the 180 Å
diameter estimated for the comparable IgM Cµ3–Cµ4 hexameric
platform (32). Local differences are observed between the differ-
ent IgG isotypes in their hexameric interface composition and
surface loop conformations (32). Of note, the IgG4 homologous
C1q-binding loop is flexible, with at least two different conforma-
tions observed. The major conformation observed in native IgG4
prevents C1q binding, which correlates with the strongly reduced
level of CP activation by native IgG4 hexamers (32).
CURRENT STRUCTURAL KNOWLEDGE ON C1 BUILDING
BLOCKS AND KEY PROTEIN–PROTEIN INTERACTIONS
Although the first C1r crystals were obtained in 1981 [cited in
Ref. (26)], X-ray crystallography analyses were initially limited,
probably because of molecular flexibility. The C1 complex and
most of its components look indeed very flexible (Figure 1C). A
dissection strategy has thus been set up to determine the high-
resolution structures of the main functional blocks (33) and of
several structural joints, as detailed in Table S1 in Supplementary
Material (Figures 1D–F). For the C1q molecule, only the X-ray
structure of the C-terminal globular domain could be obtained
(34), alone or in complex with minimal recognition motifs, such
as deoxyribose for DNA, which gave insights into its recognition
properties [reviewed previously in Ref. (35)].
More X-ray structures of C1r and C1s protease domains have
been determined (Table S1 in Supplementary Material). The struc-
tures of all C1s modules are now known (Figure 1F). Detailed
insights about conformational rearrangements were obtained by
comparing different X-ray structures, for example between pro-
enzyme and active states of the SP domains (36, 37), as well as some
variations in inter-modular orientations (5, 38). The structure of
the SP domains also revealed the main structural determinants
of their restricted substrate specificity (4, 37, 38). However, C1s
SP domain alone is not able to cleave C4 efficiently (39). C4
cleavage, which is the first step of both the classical and lectin
activation pathways, appears thus to be more stringent since it
requires additional exosites (40). The fine structural details about
exosites in MASP-2 (the equivalent of C1s in the lectin pathway)
and their interaction with C4 were unraveled recently (41). The
functional implication of the homologous CCP exosite in C1s
could be confirmed by mutational analyses (41). The structure
of the C1s exosite at the CCP1/CCP2 interface was then solved
recently (37). Interestingly, both the zymogen structure and sur-
face plasmon resonance interaction analyses suggest that the C1s
exosites are partly hidden in the pro-enzyme state (37).
Structural details of protein–protein interactions relevant in
terms of C1 assembly were also unraveled during this structural
dissection, such as the head-to-tail interaction of the C1r cat-
alytic domains. Such a dimeric interaction has been observed three
times by X-ray crystallography and the butterfly-like side view
(Figure 2A) can also be recognized at the center of early electron
micrographs of the proteases tetramer (23, 36, 42). This interac-
tion is maintained through contacts between the CCP1 module
of one C1r subunit and the SP domain of its partner (36). One
of the functional consequences is the larger than 90 Å distance
between the active site of one monomer and the scissile bond of
its partner, which prevents spontaneous mutual activation in this
dimeric context (36). This auto-inhibited assembly looks like a
“resting” state, which requires a conformational change to trigger
C1 activation (36,43). This interface between the catalytic domains
of C1r is really specific of the CP activation, with no equivalent
in the complexes activating the lectin pathway. Another structural
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FIGURE 2 | Structures of key protein/protein interactions of
C1 components. (A) Dimeric association of the C1r catalytic domains. The
interface involves similar interactions between the SP domain and the
CCP1 module, in both the pro-enzyme and active C1r catalytic domain
structures. This typical “butterfly” shape can be recognized on some
electron micrographs from the proteases tetramer (23). The 90 Å distant
active site (red ellipse) and activation site (black star) of the two molecules
are highlighted [PDB code 1GPZ (36)]. (B) Dimeric CUB1–EGF interface
(present in vitro in C1s homodimers and in vivo in C1r/C1s heterodimers).
The central EGF calcium-binding sites stabilize both the inter- and
intra-monomeric CUB-EGF interfaces (highlighted by gray rectangles). Since
interface residues are mostly conserved in C1r (compared to C1s), we can
assume that this head-to-tail packing observed with C1s homodimers also
stands for the C1s–C1r heterodimer. This typical shape can also be
recognized on some rare electron micrographs performed on the proteases
tetramer (23). Yellow sphere, calcium in EGF; green sphere, calcium or
magnesium in the C1s CUB1 module [PDB code 1NZI (45)].
(C) Calcium-dependent interaction between C1s CUB1 module and a
lysine-containing collagen-like peptide [PDB code 4LOR (5)]. The main
structural determinants are highlighted. The lysine side chain directly
interacts with Glu45, Asp98, and Ser100. Asp53 is an essential component
of the calcium-binding site. Mutations of Glu45, Tyr52, and Asp98 strongly
alter C1q-binding properties [reviewed in Ref. (46)].
feature of the C1r zymogen is the inactive occluded conformation
of its primary binding site (44).
Calcium-dependent C1 assembly is controlled by the proteases
CUB and EGF modules (47). The structural details governing
these interactions have been mainly deciphered, although slightly
indirectly. The C1r/C1s calcium-dependent interaction is medi-
ated by their CUB1 and EGF modules, which form a head-to-tail
dimer under the control of their EGF calcium-binding site (45)
(Figure 2B). The calcium ion is tightly bound to the C1s EGF mod-
ule in the context of the CUB1–EGF C1s dimeric interface, since it
could not be replaced by lanthanides during soaking experiments
used to solve the X-ray structure (45). This head-to-tail interac-
tion can also be recognized on some early electron micrographs of
the proteases tetramer (23). Unexpected calcium-binding sites are
present in the CUB domains and govern the interactions between
the proteases and the C1q collagen-like stems (45, 48). The calcium
ion associated to the C1r CUB2 modules appears to be quite labile,
although it greatly enhances the structural stability of these mod-
ules (49). Site-directed mutagenesis offered a very effective tool
to confirm and detail the essential contributions of several amino
acids in the full-length molecules: (i) It identified residues essential
for C1q binding in C1r: E49,Y56, and D102 in CUB1; D226, H228,
Y235, and D273 in CUB2. Other mutations severely affecting the
C1q interactions were observed for E45 and Y52 in C1s CUB1 (46,
48). (ii) Conversely, the lysines B61 and C58 in C1q were iden-
tified by site-directed mutagenesis as essential protease-binding
residues (50). These lysines are very close to the patient muta-
tion GlyB63Ser resulting in a C1q functional deficiency including
defective CP activation (12).
Similar CUB and EGF calcium-dependent interactions have
then been observed in the MASPs-defense collagens complexes ini-
tiating the lectin complement pathway, as well as in other unrelated
molecular systems (46, 51, 52). The structure of the C1s CUB1–
EGF–CUB2 fragment in complex with a collagen-like fragment
containing the OGKLGP sequence (O standing for hydroxypro-
line, Figure 2C) confirmed such a generic mode of association but
reveals a different orientation of the CUB2 module as compared
to MASP CUB1–EGF–CUB2 fragments (5).
WHAT REMAINS STILL ILL-DEFINED?
Only the C1r CUB modules and the C1q collagen-like domain
structures have not yet been solved at atomic resolution, but we
know at least their overall shape and scaffold through homol-
ogy and experimental analyses such as electron microscopy. The
structure of the C1q recognition domain where the three subunits
(Figure 1C) tightly interact with each other in a ACB clock-wise
order (as seen from the collagen stem) has also indirectly given
some clues about the relative ordering of the three chains in the
preceding collagen-like stem (34, 47).
The isolated fragment X-ray structures or models can be com-
bined into hypothetical C1 models (47). These C1-like models
illustrate hypotheses in the 3D space about possible modes of
C1 assembly and activation, which can then be further tested by
site-directed mutagenesis (48). These models are idealized since,
for example, C1 is always displayed as a symmetrical molecu-
lar complex although we know that it is highly flexible, which
disrupts most of its symmetrical conformation in response to
the environment. These models also aim to provide a synthetic
overall representation consistent with accumulated experimen-
tal evidences (7). For example, the model depicted in Figure 1G
accounted for the differential accessibility of lysine’s residues in
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C1q and C1 derived from mass spectrometry comparative analy-
ses as well as previous experimental knowledge (7). However, such
a dense C1 complex cannot be easily seen on electron microscopy
images (unpublished results), and thus the corresponding C1
model remains an “in silico” interpretation (as well as most of
C1 models).
Part of the “C1 paradox” has thus been elucidated since we
know most of the building block structures and also key residues
involved in C1 assembly, with now six C1q-binding sites in the pro-
tease tetramer (48). Nonetheless, details on how a flexible protease
tetramer associates with such a flexible recognition molecule, and
how C1 activation proceeds and is controlled remain ill-defined.
In contrast to the in vitro studies, C1q and C1 can be found in vivo
under flow conditions, both in the circulation and in the extra-
vascular fluid, where shear stress could affect C1 assembly and
activation (53). Moreover, observing fine structural details within
C1 still represents a real experimental challenge because of its great
flexibility and modular composition. The following questions are
thus partially unanswered: How flexible is each inter-modular
junction in vivo? Is the C1r CUB2 module only partially saturated
by calcium in vivo, and thus possibly marginally stable within C1
(49)? What is the role of the charged and flexible long insertion in
C1r EGF (54)? Which chain is at the leading, medium, and edge
position in the native C1q collagen heterotrimeric stem? What are
the relative positions between these native C1q stems and the pro-
teases CUB domains? Do the proteases stably stay attached to C1q
or is there a fast assembly/disassembly equilibrium? What drives
the spectacular conformational change of the proteases from their
elongated flexible shape in solution toward the assumed compact
C1-associated conformation? How can we observe, describe, or
deduce the details of the conformational changes involved during
C1 activation? How can we observe the transmission of the trig-
gering signal from C1q recognition to C1r activation? How can we
characterize the required C1q conformational change(s)? How is
C1r activation propagated to the successive C1s, C4, and C2 activa-
tions? How does C1-inhibitor finely control these processes? What
about C1 activation by non-immune targets in a physiological or
pathological context? How do differences in antigenic structures
and surface density precisely modulate the levels of CP activation
by the Ab-coated targets? How can we predict the classical C acti-
vation outcome when C1q binds to ligands through its globular
heads? How do pathogens interfere with C1 activation?
PERSPECTIVES
Over the years, detail after detail, the image describing the
immunoglobulins/C1 interaction is gradually emerging. But the
flexibility of the C1 molecule and its thin flexible building ele-
ments such as the collagen-like stalks make its fine details difficult
to observe. Even electron microscopy performed on C1 bound to
hexameric IgG surface clusters on liposomes did not fully over-
come the limitations due to C1 flexibility, since only four (out
of the six expected) globular densities probably corresponding to
C1q recognition domains could be consistently observed on top
of the hexameric IgG assembly (8). The collagen stems are also
too thin, fragile, and flexible to be seen on averaged density maps.
Only the position of the larger N-terminal collagen stalk remains
visible after averaging. Visible density also remains after averaging
for the region probably corresponding to the interaction domains
of C1r and C1s, which fill a continuous section inside the C1q
cone.
In conclusion, although refining the structural details of C1
assembly and activation remains a difficult challenge, this mission
does not sound definitively “impossible.” The scientific commu-
nity will probably find out new solutions to further decrypt the
fine structural details, for example by matching X-ray structures
and electron density maps obtained from new developments in
electron microscopy and associated computing strategies. The use
of recombinant C1 fragments (C1q, C1r, C1s) will be useful to
further check in detail their structure/function relationships.
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